BRAF and melanoma: In patients with advanced melanomas with BRAF V600 mutation, three different combinations of BRAFi plus MEKi have been shown to yield superior clinical outcomes over BRAFi alone: dabrafenib plus trametinib versus dabrafenib; vemurafenib plus cobimetinib versus vemurafenib; encorafenib plus binimetinib versus encorafenib [88,89].